Oxygenta Pharmaceutical Limited has announced its audited financial results for the quarter and year ended March 31, 2026, following a board meeting held on May 23, 2026. The company reported a net loss of ₹1,757.17 lakh for the financial year 2025-26, compared to a net loss of ₹1,029.83 lakh in the previous year. For the quarter ended March 31, 2026, the net loss stood at ₹170.39 lakh.

Financial Performance

Revenue from operations for the year ended March 31, 2026, increased to ₹11,298.19 lakh from ₹10,929.86 lakh in the prior year. Total revenue for the year was ₹11,326.77 lakh. The company’s total expenses rose to ₹13,544.79 lakh for FY26, up from ₹12,495.91 lakh in FY25. Finance costs for the year increased significantly to ₹477.69 lakh compared to ₹196.06 lakh in the previous year.

Board Decisions and Appointments

The board approved the appointment of Mr. Amireddy Venkatesu Reddy as an Additional Director (Executive category) for a term of three years, effective May 23, 2026, subject to shareholder approval. Additionally, Mr. Janardhana Reddy Yeddula was appointed as an Additional Director (Independent category) for a term of five years, effective from the same date, also subject to shareholder approval.

The board also appointed M/s. Suryachandra & Associates, Chartered Accountants, as Internal Auditors for the financial year 2026-27. Furthermore, M/s. Aakanksha Dubey & Co., Practicing Company Secretaries, were appointed as the Scrutinizer for the e-voting process at the ensuing Annual General Meeting.

Auditor Declaration

The statutory auditors, M/s. A.M. Reddy & D.R. Reddy, Chartered Accountants, issued an audit report with an unmodified opinion on the audited financial results for the quarter and year ended March 31, 2026. The declaration was submitted by Balasubba Reddy Mamilla, Whole-time Director, in compliance with Regulation 33 of the SEBI (LODR) Regulations, 2015.

Oxygenta pharmaceutical has filed its quarterly compliance certificate for securities dematerialization with BSE Limited, fulfilling regulatory requirements under SEBI (Depositories and Participants) Regulations, 2018. The certificate covers the quarter ended March 31, 2026, and was submitted on April 15, 2026.

Regulatory Compliance Details

The compliance certificate was filed under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. This regulation mandates companies to provide details of securities dematerialized during each quarter to all stock exchanges where their shares are listed.

Company Secretary Certification

The certificate was signed by Kumkum Bajaj, Company Secretary and Compliance Officer (Membership No.: ACS76548), who digitally signed the document on April 15, 2026. The filing confirms that all required details of securities dematerialized during the quarter have been furnished to stock exchanges where the company's shares are listed.

RTA Verification

Venture Capital and Corporate Investments Private Limited, serving as the company's Registrar and Transfer Agent (RTA), provided verification through a letter dated April 3, 2026. The RTA confirmed compliance with dematerialization procedures and proper record maintenance.

Depository Operations

The RTA certified that securities received for dematerialization were properly processed according to regulatory requirements. The verification process included:

• Mutilation and cancellation of physical certificates after due verification
• Update of depository names in company records as registered owners
• Completion of processing within 15 days of receiving valid Dematerialization Request Form (DRF) and share certificates
• Furnishing details to relevant stock exchanges

Both National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL) were updated as registered owners in the company's records, ensuring compliance with depository regulations.